New Interactive Web Tool Helps Innovators Match Formulations to Drug Delivery Technologies
Catalent Introduces "Patent Pending" FormProRx™ to Solve Formulation Challenges at AAPS
Somerset, NJ – November 7, 2013 — Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, today announced that it is to launch its new 'FormProRx' web tool on November 11th, during the forthcoming 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. This innovative web-based scientific resource has been exclusively developed by leading Catalent experts to assist drug development teams seeking to determine the optimal finished dose suited to their product based on product requirements, target indications and molecule properties. FormProRx allows users to assess multiple oral drug delivery technologies in order to establish which may be the most appropriate for their molecule.
Formulators and process development scientists can easily utilize the tool by inputting chemical characteristics and product specifications to generate recommendations based on Catalent's 75+ years of experience in bioavailability enhancement and applied drug delivery. Users can gain access to a customized report for their Active Pharmaceutical Ingredient (API) Characteristics and product requirements across 24 dimensions under the categories 'Solubility & Permeability,' 'Physiochemical Properties', 'Potent Handling' and 'API Processing.' On completing the profile, the user then immediately receives a detailed report on which drug delivery technologies could be appropriate for further investigation. Whether for a new drug or a line extension, insights from FormProRx may suggest new approaches that benefit pharmacokinetics, patient adherence or the formulation's therapeutic profile.
"It is ever more challenging to deliver drugs effectively in a form that is convenient for patients and minimizes side effects. Formulators can drive better outcomes through familiarity with the many drug delivery technologies available," commented Dr. Kurt Nielsen, Chief Technology Officer and Senior Vice President of Innovation and Growth at Catalent. "By introducing a tool that suggests drug delivery technologies based on the specific characteristics of the molecule, and yet is fast and easy-to-use, Catalent aims to help innovators improve their treatments and advance them faster. It is built on the knowledge of many scientists with broad experience developing hundreds of molecules and provides an excellent aid to development teams."